Sanofi (SNY)
| Market Cap | 111.44B |
| Revenue (ttm) | 53.71B |
| Net Income (ttm) | 10.72B |
| Shares Out | 1.22B |
| EPS (ttm) | 8.65 |
| PE Ratio | 10.40 |
| Forward PE | 9.64 |
| Dividend | $1.60 (3.51%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 13,182,576 |
| Open | 45.48 |
| Previous Close | 45.07 |
| Day's Range | 45.46 - 45.84 |
| 52-Week Range | 44.73 - 60.12 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 61.50 (+35.05%) |
| Earnings Date | Oct 24, 2025 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 35.05% from the latest price.
News
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
Sanofi Expands Insulin Savings Program To Cover All US Patients
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S...
Sanofi to offer all insulin products for $35 per month in US
French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
MORRISTOWN, N.J. , Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all pa...
French court orders Sanofi to pay $177 million for anti-competitive behaviour
A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to France's national health insurance fund (CNAM) for anti-competitive practices ...
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di...
Press release: Availability of the Q3 2025 Aide mémoire
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third q...
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three...
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e...
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help protec...
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Sanofi (NASDAQ:SNY) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila ...
Sanofi market value tanks following weak results on eczema drug trials
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab...
Why Is Sanofi Stock Falling Thursday?
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre...
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta...
Sanofi Shares Sink as Experimental Drug Results Disappoint
Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.
Sanofi shares sink over 9% on weak trial results for experimental inflammation drug
Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.
Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial
Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.
Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.